Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 34, Issue 28, 2016, Pages 3375-3382

  Oxnard, Geoffrey R ^a   Thress, Kenneth S ^b   Alden, Ryan S ^a   Lawrance, Rachael ^b   Paweletz, Cloud P ^a   Cantarini, Mireille ^b   Yang, James Chih Hsin ^c   Barrett, J Carl ^b   Jänne, Pasi A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; DACOMITINIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; OSIMERTINIB; ROCILETINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL FREE SYSTEM; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG DOSE; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PLASMA; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84990050278     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.7162     Document Type: Article

References (25)

1. Arcila ME, Oxnard GR, Nafa K, et al: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17:1169-1180, 2011
2. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
3. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
4. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26, 2011
5. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334, 2013
6. Oxnard GR, Arcila ME, Chmielecki J, et al: New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17:5530-5537, 2011
7. Soria JC, Wu YL, Nakagawa K, et al: Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial. Lancet Oncol 16:990-998, 2015
8. Cross DA, Ashton SE, Ghiorghiu S, et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046-1061, 2014
9. Zhou W, Ercan D, Chen L, et al: Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070-1074, 2009
10. Finlay MR, Anderton M, Ashton S, et al: Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 57:8249-8267, 2014
11. Ward RA, Anderton MJ, Ashton S, et al: Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J Med Chem 56:7025-7048, 2013
12. Jänne PA, Yang JC, Kim DW, et al: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689-1699, 2015
13. Murakami H, Nokihara H, Shimizu T, et al: Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation. Eur J Cancer 50:198, 2014 (suppl 6, abstr 9LBA)
14. Park K, Lee J-S, Lee KH, et al: Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). J Clin Oncol 33, 2015 (suppl 15, abstr 8084)
15. Sequist LV, Soria JC, Goldman JW, et al: Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 372:1700-1709, 2015
16. Tan DS-W, Seto T, Leighl NB, et al: First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small-cell lung cancer (NSCLC) harboring T790M. J Clin Oncol 33, 2015 (abstr 8013)
17. AstraZeneca: TAGRISSO (osimertinib) tablet: highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/208065s000lbl.pdf
18. Redig AJ, Taibi M, Oxnard GR, et al: A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression. J Clin Oncol 33, 2015 (abstr 8076)
19. Electronic Medicines Compendium: IRESSA (gefitinib) 250 mg film-coated tablets. https://www.medicines.org.uk/emc/medicine/22104
20. Thress KS, Brant R, Carr TH, et al: EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90:509-515, 2015
21. Oxnard GR, Paweletz CP, Kuang Y, et al: Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20:1698-1705, 2014
22. Douillard JY, Ostoros G, Cobo M, et al: Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9:1345-1353, 2014
23. Luo J, Shen L, Zheng D: Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: A systematic review and meta-analysis. Sci Rep 4:6269, 2014
24. Pasquale R, Fenizia F, Esposito Abate R, et al: Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics 16:1135-1148, 2015
25. Sacher AG, Paweletz C, Dahlberg SE, et al: Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol 10.1001/jamaoncol.2016.0173 [epub ahead of print on April 7, 2016]